It was a profound honor delivering the #ASCO25 President's Address during yesterday's Opening Session. Together, we are defining cancer care for generations to come with hope fueled by the many successes we achieve together at ASCO. Full address: connection.asco.org/do/2025-presid…

Hear her! Great campaign about awareness of lung cancer in women. Gracias ⁦Narjust Florez, MD, FASCO⁩ for the beutiful pin

As anticipated, SERENA-6 creates a lot of questions. PFS-2 is immature and crossover was not allowed; given PFS on postMonarch & EMBER-3 combo, it is unclear to me that early switch based on molecular disease is practice changing. #ASCO25

Fabulous discussion from Dr. Alexandra Thomas on the evolving evidence for ctDNA across the continuum of breast cancer. Roadmap to understand when and how to use ctDNA in the clinic and what studies are still very much needed before changing practice Breast International Group

Always a fun time with Narjust Florez, MD, FASCO Also there my fellow compatriota Barbara Segarra When you combine latinas together, you get supporters, cheerleaders, and fans I could not ask for a better community #FlorezLab

😇I'm thrilled and humbled to receive the Next Gen Disruptor Award. Heartfelt thanks HemOnc Today Healio! ASCO #ASCO25 #HealioInnovators 🙏I'm deeply grateful for the incredible mentors, sponsors, collaborators and friends who opened doors and supported me along the way.

Another #ASCO25 happy dance. A celebration of friends, collaboration, and a common purpose to cure cancer.

Come join us at 8am on Monday June 2 for a great educational session on advocacy! #ASCO25

#ASCO25 Day 3 Fit check (evening addition): it's always sequins for #ASCOFashion President's reception. 🤷🏻‍♀️I don't make the rules.

Wow, right? 7:30 Monday at #ASCO25. Agree! No doubt #DB09 will be practice changing. The question is, how will we handle maintenance?

The ASCO Annual Meeting is all about the science—but the real magic is in the friendships built over the years. 📸 from last night’s #ASCO25 President’s Reception with some truly amazing friends!

Particularly excited about the activity in #TNBC post topo-1 ADCs. 86% had seen savituzumab govitecan, 1/3 had seen T-DXd, 1/4 had seen both! #ASCO25 #ADC #NewTargetNewPayload

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

Today is the day! I’m so excited to present the updated data on #onc201 #dordaviprone in the setting of #H3K27m mutant diffuse glioma! this drug is under review for accelerated approval by the FDA!! Head to the peds session to hear more. #btsm #asco25

#ASCO25 #MetastaticBreastCancer Poster Session: Assessing the impact of #ScalpCooling in patients receiving #TrastuzumabDeruxtecan for metastatic #BreastCancer. Elahe Salehi DNP Abs 1095 | Poster Bd 74 | Jun 2, 9-12 PM CDT | Hall A

#ASCO25 Metastatic #BreastCancer Poster Session: Quantitative pre-treatment assessment of trastuzumab deruxtecan (#TDXd) antibody target (HER2) and payload target (topoisomerase 1, Topo1) to predict outcomes in #MetastaticBreastCancer (#MBC). Paolo Tarantino Abstract 1032 |

All of our #FlorezLab members are BUSY at work here ASCO! Day 4 is absolutely packed. Starting off the morning with Ana I. Velázquez Mañana, MD, MSc, FASCO #FASCO. She has not 1, not 2, but 3 events today! If you haven't been able to catch her, you can come support her at the following events: 1. 💬

#ASCO25 Poster Session on #MBC 👉 #DATOBase: A phase II study of DATOpotamab deruxtecan for patients with #BreastCancerBrainMetastases or #Leptomeningeal disease. Abs TPS1134 | Post Bd 106a| Jun 2 9-12 PM CDT | Hall A Paolo Tarantino Dr Sarah Sammons Sara Tolaney Nancy Lin, MD

Oyepeju Abioye-Akintola, MD, MSc is presenting her poster today on ASCO's Digital Impact-our wheelhouse as we work to up our digital footprint. 📍 Hall A | 1:30–4:30 PM Find out how digital promotion influenced JCO downloads in 2023! ASCO sponsor us? 😁 #ASCO25 #AcademicMedicine

🔔Make sure to check our study!! ASCO #ASCO25 ⭐️#HighFiber (HF) #diet to modulate microbiome and outcomes in #immunotherapy in #Melanoma ✅ORR: ⬆️HF 77% Cntrl 29% ✅No significant GI related or Immune related AEs with HF diet ✅Cutaneous adverse events⬇️ w HF ✅ impressive EFS